Clinical Trials
28 trialsNCT02998567 2026-05-12
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02935361 2026-01-29
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
Phase 1/2 Active not recruiting
NCT03257761 2025-12-05
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT02684162 2025-11-06
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03220477 2025-08-06
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03206047 2025-03-13
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02920008 2024-08-28
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT01752933 2024-08-27
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02348489 2024-08-27
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT02907359 2024-08-27
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03603964 2024-08-27
Guadecitabine Extension Study
Astex Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02901899 2024-02-20
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Northwestern University
Phase 2 Completed
NCT03913455 2023-12-20
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT03075826 2022-05-05
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Weill Medical College of Cornell University
Phase 2 Completed
NCT03308396 2022-02-17
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT03179943 2021-11-04
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT03576963 2021-04-05
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Withdrawn
NCT01966289 2021-03-30
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02293993 2021-03-05
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Otsuka Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02429466 2020-09-23
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Indiana University
Phase 1 Completed
NCT02892318 2020-03-13
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Hoffmann-La Roche
Phase 1 Completed
NCT04250246 2020-01-31
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT03085849 2018-12-10
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Columbia University
Phase 1 Completed
NCT03454984 2018-11-15
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Groupe Francophone des Myelodysplasies
Phase 2 Unknown
NCT02608437 2015-11-18
NIBIT-M4
Italian Network for Tumor Biotherapy Foundation
Phase 1 Unknown